The US Food and Drug
Administration has announced
the removal of restrictions on
prescribing and use of Avandia
(rosiglitazone) “to reflect new
information regarding the
cardiovascular risk of the medicine”.
The FDA cited the RECORD clinical
trial which showed no elevated risk
of heart attack or death in patients
being treated with Avandia when
compared to other diabetes drugs.
Previously a meta-analysis had
indicated an increased risk of heart
attacks, but the FDA said the new
results have reduced its concerns.The above article was sent to subscribers in Pharmacy Daily's issue from 27 Nov 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Nov 13
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.